StockNews.com Begins Coverage on Genocea Biosciences (NASDAQ:GNCA)

Equities research analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a report released on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Stock Performance

The firm has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a one year low of $0.00 and a one year high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.